Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Safety & Efficacy of Deferasirox Given for 1 Year in Patients With Chronic Anemias and Transfusional Hemosiderosis Unable to be Treated With Deferoxamine

Next Previous
Trial Profile

Phase II Study of Safety & Efficacy of Deferasirox Given for 1 Year in Patients With Chronic Anemias and Transfusional Hemosiderosis Unable to be Treated With Deferoxamine

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deferasirox (Primary)
  • Indications Haemosiderosis
  • Focus Therapeutic Use
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 28 Dec 2017 Data (12-month) from this controlled registration study (ICL670A108) was used to developed a model which was then applied to both deferasirox film-coated tablet (FCT) and dispersible tablet (DT) arms of ECLIPSE trial for predicting serum ferritin levels in patients from ECLIPSE trial if they continued both arms for 6-12 months, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 25 Jun 2017 Results (n=282) of retrospective analysis in subgroups of Italian patients assessing serum creatinine using patient data from the registration studies (studies 105, 106 and CICL670 0107, CICL670A0108, CICL670A0109), presented at the 22nd Congress of the European Haematology Association
    • 08 Dec 2015 Results (n=219) assessing correlation of hepatocyte iron score and liver iron ratio with alanine aminotransferase from this and other trial (see profile 248855) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top